In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.
2025年1月22日，制药公司诺和诺德（NVO）成交额为4.78亿美元，在当日美股中排第205名，成交额较昨日减少26.54%，当日成交量为590.44万。 诺和诺德（NVO）于2025年1月22日跌0.57%，报80.57美元，该股过去5个交易日跌2.83%，整个1月跌6.34%，年初至今跌6.34%，过去52周跌23.54%。
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
22 小时
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...
A man has appeared in court charged with child cruelty after a toddler was found injured at a property in Surrey. Officers ...
European stocks saw further gains on Wednesday, with Adidas (OTC:ADDYY)' robust holiday-quarter results driving German shares ...
Ameritas Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 453.3% during ...
(Reuters) - European stocks extended their recent run of gains on Wednesday, with strong holiday-quarter performance from ...
【全球首个口服GLP-1RA诺和忻（司美格鲁肽片）在中国全面上市】财联社1月11日电，诺和诺德宣布，全球首个口服胰高糖素样肽-1受体激动剂（GLP-1RA）——诺和忻（司美格鲁肽片）在中国全面上市。诺和忻以便利的口服给药方式，帮助患者更早获益于GLP-1RA类药物，助力血糖优质达标与代谢综合管理，为中国2型糖尿病临床治疗带来一个创新品类。（北京青年报） ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈